

WFS1 T321P — Wolframín

Threonine → Proline at position 321 inside TM1. ClinVar Likely pathogenic. AlphaMissense 0.261 (below threshold) — AM under-call. DynaMut2 $\Delta\Delta G$ +0.13 kcal/mol — essentially neutral. Same position as T321R, proline-introduction at TM1 start.

IDENTITY

Variant	T321P (p.Threonine321Proline)
DNA change	c.961A>C
Gene · Protein	WFS1 · Wolframín (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000918064
Amino acid change	Threonine (T) → Proline (P) — small polar hydroxyl replaced by rigid helix-breaking residue.

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 321	75.12 HIGH CONFIDENCE
Domain	TM1 (314-334), helical transmembrane
Position context	TM1 (residues 314-334) · position 321 near the start of TM1 (pLDDT 75).
IDR flag	No — pLDDT well above 50 threshold

Position 321 sits at the start of TM1. Same neighbor environment as T321R: HIS322 (2.5 Å), PRO320 (2.5 Å — adjacent proline!), ILE319 (3.8 Å), ILE324 (4.4 Å), HIS323 (4.5 Å). Replacing T321 with proline creates a Pro-Pro motif (P320-P321) in the cytoplasmic-to-TM1 boundary region. Two adjacent prolines produce a rigid backbone segment with restricted conformational options — similar to the L723P/P724S Pro-Pro region in the luminal domain. The $\Delta\Delta G$ of +0.13 (essentially neutral) reflects fold accommodation through local rearrangement. AlphaMissense's 0.261 below threshold is AM under-call. ClinVar Likely Pathogenic establishes clinical relevance.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

0.261

am_class: **LBen** —
threshold > 0.564

DYNAMUT2 $\Delta\Delta G$

0.13 kcal/mol

Stabilising · Job
177992012412

PLDDT (ALPHAFOLD)

75.12

high confidence

CLINICAL EVIDENCE

ClinVar classification

LIKELY PATHOGENIC

Review status

criteria provided, single submitter

Last evaluated

2025/03/10 00:00

Inheritance

Inheritance not specified.

WFS1 variant landscape

T321P is 1 of ~326 pathogenic-spectrum
variants in WFS1 (out of 2,243 in ClinVar)

- (no specific conditions catalogued)

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G$
2–4 → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 –
gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable
fold + functional site hit → CATEGORY 4 – site-specific docking

Category 4 — Stable Fold, Function Disrupted (AM under-call). $\Delta\Delta G = +0.13$ — fold essentially unchanged. AlphaMissense 0.261 below threshold.

Mechanism is creation of a P320-P321 Pro-Pro motif at the TM1 boundary, altering TM1 insertion geometry. Therapeutic strategy: site-directed at TM1 start.

T321P + T321R both at position 321, both AM under-calls, both ClinVar pathogenic. The dense TM1 variant cluster (W314R, H313Y, T321R, T321P, H323R, A326E) makes TM1 a high-confidence multi-variant therapeutic target.

